Condition: Soft Tissue Sarcoma Adult · Angiosarcoma · Undifferentiated Pleomorphic Sarcoma · Sponsor: Niels Junker
The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: * Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure * Baseline biopsy and further optional biopsies * Treatment propranolol 40 mg BID and pembrolizumab 2 mg/kg Q3 weeks * Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule
This description comes directly from the study's public registry record.
Niels Junker, MD, PhD · +4538682973 · Niels.Junker@regionh.dk
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus, Denmark | Not Yet Recruiting |
| Herlev Gentofte Hospital | Herlev, Denmark | Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
| Karolinska University Hospital | Stockholm, Sweden | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05961761